Antioxidant properties of melatonin and its potential action in diseases

Current Topics in Medicinal Chemistry

Volumn 15, Issue 9, 2015, Pages 894-903

  Karaaslan, Cigdem ^a   Suzen, Sibel ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Cancer; Diabetes; Immune system; Inflammatory diseases; Melatonin; Neurodegenerative disorders; Radiation

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLUTATHIONE REDUCTASE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MEMBRANE RECEPTOR; OLANZAPINE; PEROXIDASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIPOLAR DISORDER; CELL DAMAGE; CELL PROTECTION; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASES; DNA DAMAGE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; IONIZING RADIATION; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PSORIASIS; ULTRAVIOLET RADIATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; NEURODEGENERATIVE DISEASES; RADIATION INJURIES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; MELATONIN; NEOPLASMS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PSORIASIS; RADIATION INJURIES;

EID: 84928914194     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150220120946     Document Type: Article

References (112)

1. Reiter, R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev., 1991, 12. 151-180
2. Pacchierotti, C.; Iapichino, S.; Bossini, L.; Pieraccini, F.; Castrogiovanni, P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol, 2001 22:18–32
3. Bonnefont-Rousselot, D.; Collin, F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology, 2010, 278:55–67
4. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Koppisepi, S. Medical implications of melatonin: receptormediated and receptor independent actions. Adv. Med. Sci., 2007, 52: 11–28
5. OZAKIY, LYNCHHJ. Presence of melatonin in plasma and urine or pinealectomized rats. Endocrinology, 1976, 99: 641–644
6. Tosini, G.; Owino, S.; Guillaume, J.L.; Jockers, R. Understanding Melatonin Receptor Pharmacology: Latest Insights From Mouse Models, And Their Relevance To Human Disease, Bioessays, 2014, 36(8):778–787
7. Hardeland, R.; Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin-A Pleiotropic, Orchestrating Regulator Molecule, Progress in Neurobiology, 2011,93: 350–384
8. Singh, M.; Jadhav, H.R. Melatonin: Functions and Ligands, Drug Discovery Today, 2014
9. Cipolla-Neto, J.; Amaral, F. G.; Afeche, S. C.; Tan, D. X.; Reiter, R. J. Melatonın, Energy Metabolısm, and Obesıty: A Revıew, J. Pineal Res., 2014, 56:371–381
10. Tan, D.X.; Manchester, L.C.; Hardeland, R.; Lopez-Burillo, S.; Mayo, J.C.; Sainz, R.M.; Reiter, R.J. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal. Res. 2003, 34: 75-78
11. Hardeland, R.; Tan, D.X.; Reiter, R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal. Res., 2009, 47: 109-126
12. Reiter, R.J.; Melchiorri, D.; Sewerynek, E.; Poeggeler, B.; Barlow- Walden, L.; Chuang, J.; Ortiz, G.G., Acuna-Castroviejo, D., A review of the evidence supportingmelatonin’s role as an antioxidant. 1995, J. Pineal. Res. 18: 1–11
13. Reiter, R.J. Aging And Oxygen Toxicity: Relation To Changes In Melatonin. Age, 1997, 20:201–213
14. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.M.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature’s Most Versatile Biological Signal? FEBS, J. 2006, 273: 2813–2838
15. Vielma, J.R.; Bonilla, E.; Chacin-Bonilla, L.; Moraa, M.; Medina- Leendertza, S.; Bravo, Y. Effects Of Melatonin On Oxidative Stress, And Resistance To Bacterial, Parasitic, And Viral Infections: A Review, Acta Tropica, 2004, 137: 31–38
16. Cardinali, D.P.; Vigo, D.E.; Olivar, N.; Vidal, M.F.; Brusco, L.I. Melatonin Therapy in Patients with Alzheimer’s disease, Antioxidants, 2004, 3: 245-277
17. Acuña-Castroviejo, D.; Reiter, R.J.; Menéndez-Peláez, A.; Pablos, M.I.; Burgos, A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. 1994, J. Pineal. Res. 16:100-112
18. FRANK, L. Oxygen toxicity in eukaryotes. In: Oberly, L.W. (Ed.), Superoxide dismutase, pathological states, CRC Press, Boca Raton, 1985, 3:1–43
19. Hardeland, R. Melatonin and theories of ageing: a critical appraisal of melatonin’s role in antiaging mechanism. J. Pineal Res. 2003, 55: 325–356
20. Hardeland, R. Antioxidant protection by melatonin. Endocrine. 2005, 27: 119–130
21. Harman, D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11: 298–300
22. Johns, J.R.; Latts, J.A. Theoretical insight into the antioxidant properties of melatonin and derivatives. Org. Biomol. Chem., 2014, 12:7820-7827
23. Galano, A.; T, D.X.; Reiter, R.J. Cyclic 3-hydroxymelatonin, a key metabolite enhancing the peroxyl radical scavenging activity of melatonin. RSC Adv., 2014, 4: 5220-5227
24. Molina-Carballo, A.; Muñoz-Hoyos, A.; Reiter, R. J.; Sánchez- Forte, M.; Moreno-Madrid, F.; Rufo-Campos, M.; Acuna- Castroviejo, D. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J. Pineal Res., 1997, 23(2): 97-105
25. Kazuhiro, H. High dose melatonin therapy for patients with extremely intractable epilepsy. Neurol. Asia, 2004, 9 (Supplement 1), 114,
26. Sheldon, S.H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet, 1998, 351:1254-1264
27. Rodriguez, C.; Mayo, J.C.; Sainz, R.M.; Antolin, I.; Herrera, F.; Martin, V.; Reiter, R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal. Res., 2004, 36: 1-9
28. Reiter, R.J.; Tan, D.X.; Osuna, C.; Gitto, E. Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci., 2000, 7: 444-458
29. Tan, D. X.; Chen, L. D.; Poeggeler, B.; Manchester, L. C.; Reiter, R. J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J., 1993, 1(4):57-60
30. Galano, A.; Tan, D. X.; Reiter, R. J. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal. Res., 2013, 54(3): 245-257
31. Krokosz, A.; Grebowski, J.; Szweda-Lewandowska, Z.; Rodacka, A.; Puchala, M. Can Melatonin Delay Oxidative Damage Of Human Erythrocytes During Prolonged Incubation? Adv. Med. Sci., 2013, 58(1):134-142
32. Tan, D. X.; Manchester, L. C.; Terron, M. P.; Flores, L. J.; Reiter, R. J. One molecule, many derivatives: A never_ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007 42(1): 28-42
33. Gulcin, I.; Beydemir, S.; Hisar, O.; Koksal, E.; Reiter, R.J. Melatonin administration increases antioxidant enzymes activities and reduces lipid peroxidation in the rainbow trout (Oncorhynchus mykiss, Walbaum) erythrocytes. Turk. J. Vet. Anim. Sci., 2009, 33(3):241-245
34. Bharti, V.K.; Srivastava, R.S.; Kumar, H.; Bag, S.; Majumdar, A.C.; Singh, G.; Pandi-Perumal, S.R.; Brown, G.M. Effects of Melatonin and Epiphyseal Proteins on Fluoride-Induced Adverse Changes in Antioxidant Status of Heart, Liver, and Kidney of Rats. Adv. Pharmacol. Sci., 2014:1-6
35. Chakravarty, S.; Rizi, S.I. Day and Night GSH and MDA Levels in Healthy Adults and Effects of Different Doses of Melatonin on These Parameters. Int. J. Cell Biol., 2011:1-5
36. Sander, C.S.; Chang, H.; Hamm, F.; Elsner, P.; Thiele, J.J. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int. J. Dermatol., 2004, 43: 326-335
37. Nishigori, C.; Hattori, Y.; Toyokuni, S. Role of reactive oxygen species in skin carcinogenesis. Antioxid Redox Signal, 2004, 6: 561–570
38. Fischer, T.W.; Slominski, A.; Zmijewski, M.A.; Reiter, R.J.; Paus, R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp. Dermatol., 2008, 17: 713–730
39. Scheuer, C.; Pommergaard, H.C.; Rosenberg, J.; Gogenur, I. Melatonin’s Protective Effect Against Uv Radiation: A Systematic Review Of Clinical And Experimental Studies, Photodermatol Photoimmunol Photomed., 2014, 30: 180–188
40. Karbownik, M.; Reiter, R.J. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc. Soc. Exp. Biol. Med., 2000, 225(1):9-22
41. Sener, G.; Atasoy, B.M.; Ersoy, Y.; Arbak, S.; Sengöz, M.; Yeğen, B.C. Melatonin protects against ionizing radiation-induced oxidative damage in corpus cavernosum and urinary bladder in rats. J. Pineal. Res., 2004, 37(4):241-6
42. Koc, M.; Buyukokuroglu, M.E.; Taysi, S. The effect of melatonin on peripheral blood cells during total body irradiation in rats. Biol. Pharm. Bull. 2002, 25(5):656–657
43. Mihandoost, E., Shirazi A., Mahdavi S.R., Alisgharzadeh, A. Can Melatonin Help Us in Radiation Oncology Treatments?. BioMed Research Int., 2014, 1-12
44. Szczepanik, M., Melatonin and Its, Influence On Immune System, J. Physiol. Pharmacol., 2007, 58(6): 115-124
45. Lissoni, P.; Rovelli, F.; Brivio, F.; Fumagalli, L.; Brera, G. A study of immunoendocrine strategies with pineal indoles and interleukin- 2 to prevent radiotherapy-induced lymphocyt openia in cancer patients. In vivo, 2008, 22: 397–400
46. Esposito, E.; Cuzzocrea, S. Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol., 2010, 8(3):228–242
47. Kostoglou-Athanassiou, I. Therapeutic applications of melatonin. Ther. Adv. Endocrinol. Metab., 2013, 4(1):13–24
48. Cermakian, N.; Westfall, S.; Kiessling, S. Circadian Clocks And Inflammation: Reciprocal Regulation And Shared Mediators, Arch. Immunol. Ther. Exp., 2014, 62, 303–318
49. Morrey, K.M.; Mclachlan, J.A.; Serkin, C.D.; Bakouche, O. Activation of human monocytes by the pineal hormone melatonin. J. Immunol., 1994, 153: 2671–2680
50. Carrillo-Vico, A.; Lardone, P.J.; Naji, L.; Fernandez-Santos, J.M.; Martin-Lacave, I.; Guerrero, J.M.; Calvo, J.R. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J. Pineal Res., 2005, 39: 400–408
51. Cristofanon, S.; Uguccioni, F.; Cerella, C.; Radogna, F.; Dicato, M.; Ghibelli, L.; Diederich, M. Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kB activation. Ann. N. Y. Acad. Sci., 2009, 1171: 472–478
52. Radogna, F.; Paternoster, L.; De Nicola, M.; Cerella, C.; Ammendola, S.; Bedini, A.; Tarzia, G.; Aquilano, K.; Ciriolo, M.; Ghibelli, L. Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes. Toxicol. Appl. Pharmacol., 2009, 239: 37–45
53. Radogna, F.; Sestili, P.; Martinelli, C.; Paolillo, M.; Paternoster, L.; Albertini, M.C.; Accorsi, A.; Gualandi, G.; Ghibelli, L. Lipoxygenase- mediated pro-radical effect of melatonin via stimulation of arachidonic acid metabolism. Toxicol. Appl. Pharmacol., 2009, 238:170–177
54. Mauriz, J.L.; Collado, P.S.; Veneroso, C.; Reiter, R.J.; González- Gallego, J. A review of the molecular aspects of melatonin’s antiinflammatory actions: recent insights and new perspectives. J. Pineal Res., 2013, 54: 1–14
55. Drazen, D.L.; Bilu, D.; Bilbo, S.D. Melatonin enhancement of splenocyte proliferation is attenuated by luzindole, a melatonin receptor antagonist. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 280: R1476–R1482
56. Chandran, V.; Raychaudhuri, S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J. Autoimmunity, 2010, 34: 314–21
57. Grivas, T.B.; Savvidou, O.D. Melatonin the “light of night” in human biology and adolescent idiopathic scoliosis. Scoliosis, 2007, 2:1–14
58. Fischer, T.; Wigger-Alberti, W.; Elsner, P. Melatonin in dermatology. Experimental and clinical aspects. Hautarzt, 1999, 50(1): 5-11
59. Kartha, L. B.; Chandrashekar, L.; Rajappa, M.; Menon, V.; Thappa, D.M. and. Ananthanarayanan, P.H., Serum Melatonin Levels In Psoriasis And Associated Depressive Symptoms, Clin. Chem. Lab. Med., 2014, 52(6): 123–125
60. Adamczyk-Sowa, M.; Pierzchala, K.; Sowa, P.; Mucha, S.; Sadowska-Bartosz, I.; Adamczyk, J.; Hartel, M. Melatonin Acts As Antioxidant And Improves Sleep In Ms Patients, Neurochem. Res., 2014, 39(8):1585-93
61. MEHTA, B.K. New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. J. Neurol. Sci., 2010, 292(1–2): 5–10
62. Golan, D.; Staun-Ram, E.; Glass-Marmor, L.; Lavi, I.; Rozenberg, O.; Dishon, S.; Barak, M.; Ish-Shalom, S.; Miller, A. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav. Immun., 2013, 32:180–185
63. Miller, E.; Walczak, A.; Majsterek, I.; Kędziora, J. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J. Neuroimmunol., 2013, 257(1) 97-101
64. Reiter, R.J.; Garcia, J.J.; Pie, J. Oxidative toxicity in models ofneurodegeneration: Responses to melatonin. Restor. Neurol. Neurosci., 1998, 12:135–142
65. Johnson, E.J.; Vishwanathan, R.; Johnson, M.A.; Hausman, D.B.; Davey, A.; Scott, T.M.; Green, R.C.; Miller, L.S.; Gearing, M.; Woodard, J. Relationship between serum and brain carotenoids, α- tocopherol, and retinol concentrations and cognitive performance in the oldest old from the Georgia Centenarian Study. J. Aging Res., 2013, doi:10.115/951786
66. Anderson G.; Maes, M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol. Disord. Drug Targets, 2014 13(5):817-27
67. Dies, H.; Toppozini, L.; Rheinstädter, M.C. The interaction between amyloid-β peptides and anionic lipid membranes containing cholesterol and melatonin. PLoS One, 2014, 9 (6): e99124
68. Chojnacki, J.E.; Liu, K.; Yan, X.; Toldo, S.; Selden, T.; Estrada, M.; Rodríguez-Franco, M.I.; Halquist, M.S.; Ye, D.; Zhang, S. Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5- methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin. ACS Chem. Neurosci., 2014, 5(8):690-9
69. López-Iglesias, B.; Pérez, C.; Morales-Garcia, J.A.; Alonso-Gil, S.; Pérez-Castillo, A.; Romero, A.; López, M.G.; Villarroya, M.; Conde, S.; Rodriguez-Franco, M.I. New melatonin-N,Ndibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. J. Med. Chem., 2014, 57(9): 3773-85
70. Abbott, R.D.; Ross, G.W.; White, L.R.; Tanner, C.M.; Masaki, K.H.; Nelson, J.S. Excessive daytime sleepiness and subsequent development of Parkinsondisease. Neurology, 2005, 65:1442–6
71. DATTA, S. Cellular and chemical neuroscience of mammalian sleep. Sleep Med., 2010, 11:431–40
72. Gjerstad, M.D.; Aarsland, D.; Larsen, J.P. Development of daytime somnolence over time in Parkinson’s disease. Neurology, 2002, 58:1544–6
73. De Cock, V.C.; Vidailhet, M.; Arnulf, I. Sleep disturbances in patients with parkinsonism. Nat. Clin. Pract. Neurol., 2008, 4:254-66
74. Postuma, R.B.; Bertrand, J.A.; Montplaisir, J.; Desjardins, C.; Vendette, M.; Romenets, S.R. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson’s disease: a prospective study. Mov. Disord., 2012, 27: 720–6
75. Wu, Y.H.; Swaab, D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med., 2007, 8:623–36
76. Fertl, E.; Auff, E.; Doppelbauer, A.; Waldhauser, F. Circadian secretion pattern of melatonin in Parkinson’s disease. J. Neural. Transm. Park Dis. Dement. Sect., 1991, 3:41–7
77. Bordet, R.; Devos, D.; Brique, S; Touitou, Y; Guieu, J.D.; Libersa, C. Study of circadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin. Neuropharmacol, 2003, 26:65–72
78. Bolitho, S.J.; Naismith, S.L.; Rajaratnam, S.M.W.; Grunstein, R.R.; Hodges, J.R.; Terpening, Z.; Rogers, N.; Lewis, S.J.G. Disturbances In Melatonin Secretion And Circadian Sleep–Wake Regulation In Parkinson Disease, Sleep Medicine, 2014, 15: 342–347
79. Polimeni, G.; Esposito, E.; Bevelacqua, V.; Guarneri, C.; Cuzzocrea, S. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci., 2014, (Landmark Ed). 19:429-46
80. Chen, L.J.; Gao, Y.Q.; Li, X.J.; Shen, D.H.; Sun, F.Y. Melatonin protects against MPTP/MPP+ -induced mitochondrial DNA oxidative damage in vivo and in vitro. J. Pineal. Res., 2005, 39:34-42
81. Leboyer, M.; Kupfer, D.J. Bipolar disorder: new perspectives in health care and prevention. J. Clin. Psychiatry, 2010, 71: 1689–95
82. Sugden, D. Psychopharmacological effects of melatonin in mouse and rat. J. Pharmacol. Exp. Ther., 1983, 227: 587–91
83. Bano Otalora, B; Popovic, N; Gambini, J; Popovic, M; Vina, J; Bonet-Costa, V; Reiter, Rj; Camello, Pj; Rol, Má; Madrid, Ja. Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon. Chronobiol. Int., 2012, 29: 822–34
84. Mostafavi, A.; Solhi, M.; Mohammadi, M.R.; Hamedi, M.; Keshavarzi, M.; Akhondzadeh, S. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta. Med. Iran. 2014, 52(10):734-9
85. Romo-Nava, F.; Alvarez-Icaza, G.D.; Fresán-Orellana, A.; Saracco A.R.; Becerra-Palars, C.; Moreno, J.; Uribe, O.M.P.; Berlanga, C.; Heinze, G.; Buijs, R.M. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014, 16(4):410-21
86. Smeraldi, E.; Delmonte, D. Agomelatine in depression. Expert Opin. Drug Saf. 2013, 12(6):873-80
87. Souza, L.C.; Wilhelm, E.A.; Bortolatto, C.F.; Nogueirac, C.W.; Boeira, S.P.; Jess, C.R. The Protective Effect Of Melatonin Against Brain Oxidative Stress And Hyperlocomotion In A Rat Model Of Manıa Induced By Ouabaın, Behavioural Brain Research, 2014, 271: 316–32
88. Amaral, F.G.; Turati, A.O.; Barone, M.; Scialfa, J.H.; Buonfiglio, D.C.; Peres, R.; Peliciari-Garcia, R.A.; Afeche, S. C.; Lima, L.; Scavone, C.; Bordin, S.; Reiter, R.J.; Menna-Barreto, L. And Cipolla-Neto, J. Melatonin Synthesis Impairment As A New Deleterious Outcome Of Diabetes-Derived Hyperglycemia, J. Pineal Res.2014, 57: 67–79
89. Niedowicz, D.M.; Daleke, D.L. The role of oxidative stress in diabetic complications. Cell Biochem And Biophys., 2005, 43(2): 289-330
90. Faria, J.A.; Kinote, A.; Ignacio-Souza, L.M.; De Araujo, T.M. Melatonin acts through MT1/MT2 receptors to activate hypothalamic Aktand suppress hepatic gluconeogenesis in rats. Am. J. Physiol. Endocrinol. Metab., 2013, 305: E230–42
91. Lima, F.B.; Matsushita, D.H.; Hell, N.S.; Dolnikoff, M.S. The regulation of insulin action in isolated adipocytes. Role of the periodicity of food intake, time of day and melatonin. Braz. J. Med. Biol. Res., 1994, 27: 995–1000
92. Amin, A.H.; El-Missiry, M.A.; Othman, A.I. Melatonin ameliorates metabolic risk factors, modulates apoptotic proteins, and protects the rat heart against diabetes-induced apoptosis. Eur. J. Pharmacol., 2014, 12; 747C: 166-173
93. Tresguerres, J.A.; Cuesta, S.; Kireev, R.A.; Garcia, C.; Acuna- Castroviejo, D.; Vara, E. Beneficial effect of melatonin treatment on age-related insulin resistance and on the development of type 2 diabetes. Horm. Mol. Biol. Clin. Investig., 2013, 16(2): 47-54
94. Mozdzan, M.; Mozdzan, M.; Chalubınskı, M.; Wojdan, K.; Broncel, M. The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension. Arch. Med. Sci., 2014 29 10(4):669-75
95. She, M., Laudon, M., Yin, W. Melatonin Receptors In Diabetes: A Potential New Therapeutical Target? Eur. J. Pharmacol., 2014, 744:220-3
96. Teodoro, B.G.; Baraldi, F.G.; Sampaio, I.H.; Bomfim, L.H.; Queiroz, A.L.; Passos, M.A.; Carneiro, E.M.; Alberici, L.C.; Gomis, R.; Amaral, F.G.; Cipolla-Neto, J.; Araújo, M.B.; Lima, T.; Akira, Uyemura S.; Silveira, L.R.; Vieira, E. Melatonin prevents mitochondrial dysfunction and insulin resistance in rat skeletal muscle. J. Pineal. Res., 2014, 57(2):155-67
97. McMullan, C.J.; Schernhammer, E.S.; Rimm, E.B.; Hu, F.B.; Forman, J.P. Melatonin secretion and the incidence of type 2 diabetes. JAMA, 2013, 309(13):1388-96
98. Cos, S.; Martínez-Campa, C.; González, A.V.; Alvarez-García, V.; Alonso-González, C.; Mediavilla, M.D., And Sánchez-Barceló, E.J. Melatonin And Aromatase In Breast Cancer, Clin. Cancer Drugs, 2014, 1:54-64
99. Hrushesky, W. Tumor cronobiology. J. Control Release, 2001, 74: 27-30
100. Reiter, R.J. The pineal and its hormones in the control of reproduction in mammals. Endocr. Rev.,1980, 1: 109-31
101. Cos, S; Sánchez-Barceló, Ej. Melatonin and mammary pathological growth. Front. Neuroendocrinol., 2000, 21: 133-70
102. Sánchez-Barceló Ej; Cos, S; Fernández, R; Mediavilla, MD. Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer, 2003, 10: 153-9
103. Paroni, R.; Terraneo, L.; Bonomini, F.; Finati, E.; Virgili, E.; Bianciardi, P.; Favero, G.; Fraschini, F.; Reite, R.J.; Rezzani, R; Samaja, M. Antitumour Activity Of Melatonin İn A Mouse Model Of Human Prostate Cancer: Relationship With Hypoxia Signalling, J. Pineal. Res., 2014, 57:43–52
104. Mediavilla, M.D.; Sanchez, E.J.; Tan, D.X.; Manchester, L.; Reiter, R.J. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem., 2010, 17, 4462-4481
105. Cutando, A.; Lopez-Valverde, A.; Vicente, J.; Gimenez, J.L.; Carcía, I.A; Diego, R.G. Action of melatonin on squamous cell carcinoma and other tumors of the oral cavity (Review). Oncology Lett., 2014, 7, 923-926
106. Sánchez-Barceló, E.J; Cos, S.; Mediavilla, MD.; Martinez-Campa, CM.; González, A.; Alonso-González, C. Melatonin-estrogen interactions in breast cancer. J. Pineal. Res., 2005, 38, 217-22
107. Lissoni, P.; Rovelli, F.; Malugani, F.; Bucovec, R.; Conti, A.; Maestroni, G.J.M. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrin Lett., 2001, 22(1):45–47
108. Cui, P.; Luo, Z.; Zhang, H.; Su, Y.; Li, A.; Li, H.; Zhang, J.; Yang, Z.; Xiu, R. Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J. Pineal. Res., 2006, 41(4),358–362
109. Martin-Renedo, J.; Mauriz, J.L.; Jorquera, F.; Ruiz-Andrés, O.; González, P.; González-Gallego, J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J. Pineal. Res., 2008, 45(4), 532–540
110. Jang, S.S.; Kim, W.D.; Park, W.Y. Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells. J. Pineal. Res., 2009, 47(2), 147–155
111. Martinez, G.R.; Almeida, E.A.; Klitzke, C.F.; Onuki, J.; Prado, F.M.; Medeiros, M.H.; Di Mascio, P. Measurement of melatonin and its metabolites: importance for the evaluation of their biological roles. Endocrine, 2005, 27, 111-8
112. Campbell, A.; Smith, M.A.; Sayre, L.M.; Bondy, S.C.; Perry, G. Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Res. Bull., 2001, 55, 125-32.